Status and progress of new PET-CT probe application in gastric cancer

doi:10.3877/cma.j.issn.1674-3946.2019.02.031

Abstract

Abstract:

Gastric cancer is a common malignant tumor in China, which has the characteristics of low survival rate and high morbidity, and its 10-year survival rate is about 15%. Therefore, it needs timely and accurate diagnosis and treatment. In recent decades, positron emission tomography (PET) using ¹⁸F-fluorine deoxidization glucose (¹⁸F-FDG) as a tracer has been proved to be available in a variety of malignant tumor diagnosis and evaluation to provide information about tumor metabolism. However, because of the physical uptake of gastric mucosa and voluntary exercise, some types of gastric malignant tumors may affect the detection ability of ¹⁸F-FDG in gastric cancer. Therefore, searching for more tumor-specific PET-CT imaging agents to make up for the deficiency of ¹⁸F-FDG is the focus of current nuclear medicine research. In this paper, the application status and prospect of this method in tracer of gastric cancer are reviewed.

Key words: Stomach neoplasms, Positron-emission tomography, Computed tomography, Radioactive tracers

Zhengyang Yang, Song Liu, Shichao Ai, Wenxian Guan. Status and progress of new PET-CT probe application in gastric cancer[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2019, 13(02): 209-214.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhpwkssxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3946.2019.02.031

https://zhpwkssxzz.cma-cmc.com.cn/EN/Y2019/V13/I02/209

Figures/Tables 3

References 80

[1]	Cancer Genome Atlas Research Network.Comprehensive molecular characterization of gastric adenocarcinoma[J]．Nature，2014，513(7517):202-209.
[2]	Kitajima K，Nakajo M，Kaida H，et al.Present and future roles of FDG－PET/CT imaging in the management of gastrointestinal cancer: an update[J]．Nagoya J Med Sci，2017 79(4): 527-543.
[3]	Bar－Shalom R，Yefremov N，Guralnik L，et al.Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management[J]．J Nucl Med，2003，44(8):1200-1209.
[4]	Ajani JA，D'Amico TA，Almhanna K，et al.Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology[J]．J Natl Compr Canc Netw，2016 ，14(10):1286-1312.
[5]	Waddell T，Verheij M，Allum W，et al.Gastric cancer: ESMO－ESSO－ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow－up[J]．Ann Oncol，2013，24 (Suppl 6):vi57-63.
[6]	Wu CX，Zhu ZH.Diagnosis and evaluation of gastric cancer by positron emission tomography[J]．World J Gastroenterol，2014，20(16):4574-4585.
[7]	Chen W．Clinical applications of PET in brain tumors[J]．J Nucl Med，2007 ，48(9):1468-1481.
[8]	Kato T, hinoda J，Nakayama N，et al.Metabolic assessment of gliomas using 11C－methionine, ^18Ffluorodeoxyglucose, and 11C－choline positron－emission tomography[J]．AJNR Am J Neuroradiol，2008，29(6):1176-1182.
[9]	Singhal T，Narayanan TK，Jacobs MP，et al.1C－methionine PET for grading and prognostication in gliomas: a comparison study with 18F－FDG PET and contrast enhancement on MRI[J]．J Nucl Med，2012，53(11):1709-1715.
[10]	Zhang Y，Hong H，Cai W．PET tracers based on Zirconium－89[J]．Curr Radiopharm，2011，4(2):131-139.
[11]	Kim JC，Roh SA，Koo KH，et al.Enhancement of colorectal tumor targeting using a novel biparatopic monoclonal antibody against carcinoembryonic antigen in experimental radioimmunoguided surgery[J]．Int J Cancer，2002，97(4):542-547.
[12]	Mery CM，Shafi BM，Binyamin G．Molecular imaging and radioimmunoguided surgery[J]．Semin Pediatr Surg，2006，15(4):259-266.
[13]	Jemal A，Bray F，Center MM，et al.Global cancer statistics[J]．CA Cancer J Clin，2011 ，61(2):69-90.
[14]	Nadauld LD，Ford JM.Molecular profiling of gastric cancer: toward personalized cancer medicine[J]．J Clin Oncol，2013，31(7):838-839.
[15]	Lee HS，Cho SB，Lee HE，et al.Protein expression profiling and molecular classification of gastric cancer by the tissue array method[J]．Clin Cancer Res，2007，13(14):4154-4163.
[16]	Kim MA，Lee HS，Lee HE，et al.EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number[J]．Histopathology，2008，52(6):738-746.
[17]	Terashima M，Kitada K，Ochiai A，et al.Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer[J]. Clin Cancer Res，2012，18(21):5992-6000.
[18]	Yang W，Raufi A，Klempner SJ.Targeted therapy for gastric cancer: molecular pathways and ongoing investigations[J]．Biochim Biophys Acta，2014，1846(1):232-237.
[19]	Roskoski R Jr.The ErbB/HER family of protein－tyrosine kinases and cancer[J]. Pharmacol Res，2014，79:34-74.
[20]	Ciardiello F，Damiano V，Bianco R，et al.Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A[J]．J Natl Cancer Inst，1996，88(23):1770-1776.
[21]	Mendelsohn J, Baselga J．Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer[J]．J Clin Oncol，2003，21(14):2787-2799.
[22]	Cai W，Chen K，He L，et al.Quantitative PET of EGFR expression in xenograft－bearing mice using 64Cu－labeled cetuximab, a chimeric anti－EGFR monoclonal antibody[J]. Eur J Nucl Med Mol Imaging，2007，34(6):850-858.
[23]	Schechter NR，Wendt RE 3rd，Yang DJ，et al.Radiation dosimetry of 99mTc－labeled C225 in patients with squamous cell carcinoma of the head and neck[J]. J Nucl Med, 2004，45(10):1683-1687.
[24]	Razumienko EJ，Chen JC，Cai Z，et al.Dual－Receptor－Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu－ or 111In－Labeled Bispecific Radioimmunoconjugates[J]．J Nucl Med, 2016，57(3):444-452.
[25]	Song IH，Lee TS，Park YS，et al.Immuno－PET Imaging and Radioimmunotherapy of 64Cu－/177Lu－Labeled Anti－EGFR Antibody in Esophageal Squamous Cell Carcinoma Model[J]．J Nucl Med，2016，57(7):1105-1111.
[26]	Friedman M，Orlova A，Johansson E，et al.Directed evolution to low nanomolar affinity of a tumor－targeting epidermal growth factor receptor－binding affibody molecule[J]．J Mol Biol，2008，376(5):1388-1402.
[27]	Tolmachev V，Friedman M，Sandstrom M，et al.Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry[J]．J Nucl Med，2009，50(2):274-283.
[28]	Garousi J，Andersson KG，Mitran B，et al.PET imaging of epidermal growth factor receptor expression in tumours using 89Zr－labelled ZEGFR：2377 affibody molecules[J]. Int J Oncol，2016，48(4):1325-1332.
[29]	Summer D，Garousi J，Oroujeni M, et al.Cyclic versus Noncyclic Chelating Scaffold for 89Zr－Labeled ZEGFR：2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression[J]．Mol Pharm，2018，15(1):175-185.
[30]	Pegram MD，Pauletti G，Slamon DJ.HER－2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Research and Treatment[J].1998, 52(1-3):65-77.
[31]	Freudenberg JA，Wang Q，Katsumata M，et al.The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2－targeted therapies[J]．Exp Mol Pathol，2009，87(1):1-11.
[32]	Kim JW，Im SA，Kim M，et al.The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first－line modified FOLFOX－6 regimen[J]. Anticancer Res，2012；32(4):1547-1553.
[33]	Kim MA，Lee HS，Lee HE，et al.EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology[J]. 2008，52(6):738-746.
[34]	Terashima M，Kitada K，Ochiai A，et al.Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer[J]. Clin Cancer Res，2012，18(21):5992-6000.
[35]	Kleer CG，van Golen KL，Braun T，et al.Persistent E－cadherin expression in inflammatory breast cancer[J]．Mod Pathol，2001，14(5):458-464.
[36]	Stumpp MT，Amstutz P．DARPins: a true alternative to antibodies[J]．Curr Opin Drug Discov Devel，2007，10(2):153-159.
[37]	Zahnd C，Kawe M，Stumpp MT，et al.Efficient tumor targeting with high－affinity designed ankyrin repeat proteins: effects of affinity and molecular size[J]．Cancer Res，2010，70(4):1595-1605.
[38]	Jost C，Schilling J，Tamaskovic R，et al.Structural basis for eliciting a cytotoxic effect in HER2－overexpressing cancer cells via binding to the extracellular domain of HER2[J]．Structure，2013，21(11):1979-1991.
[39]	Goldstein R，Sosabowski J，Livanos M，et al.Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging[J]．Eur J Nucl Med Mol Imaging，2015，42(2):288-301.
[40]	田颖.18F标记预设计锚蛋白重复蛋白靶向HER2的PET显像研究[D]．广州：南方医科大学，2016.
[41]	Orlova A，Magnusson M，Eriksson TL，et al.Tumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule[J]．Cancer Res，2006，66(8):4339-4348.
[42]	Xu Y，Bai Z，Huang Q，et al.PET of HER2 Expression with a Novel 18FAl Labeled Affibody[J]．J Cancer，2017，8(7):1170-1178.
[43]	Heskamp S，Laverman P，Rosik D，et al.Imaging of human epidermal growth factor receptor type 2 expression with 18F－labeled affibody molecule ZHER2：2395 in a mouse model for ovarian cancer[J]．J Nucl Med，2012，53(1):146-153.
[44]	Glaser M，Iveson P，Hoppmann S，et al.Three methods for 18F labeling of the HER2－binding affibody molecule Z(HER2：2891) including preclinical assessment[J]．J Nucl Med，2013，54(11):1981-1988.
[45]	Vu T，Claret FX.Trastuzumab: updated mechanisms of action and resistance in breast cancer[J]．Front Oncol，2012，2:62.
[46]	Hudis CA.Trastuzumab－－mechanism of action and use in clinical practice[J]．N Engl J Med，2007，357(1):39-51.
[47]	Kurokawa Y，Sugimoto N，Miwa H，et al.Phase II study of trastuzumab in combination with S－1 plus cisplatin in HER2－positive gastric cancer (HERBIS－1) [J]．Br J Cancer，2014，110(5):1163-1168.
[48]	Janjigian YY，Viola－Villegas N，Holland JP，et al.Monitoring afatinib treatment in HER2－positive gastric cancer with 18F－FDG and 89Zr－trastuzumab PET[J]．J Nucl Med, 2013，54(6):936-943.
[49]	Gebhart G，Flamen P，De Vries EG，et al.Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2[J]．J Nucl Med，2016，57 Suppl 1:81S-88S.
[50]	Holland JP，Caldas－Lopes E，Divilov V，et al.Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr－DFO－trastuzumab[J]．PLoS One，2010，5(1):e8859.
[51]	Sijbrandi NJ，Merkul E，Muns JA，et al.A Novel Platinum(II)－Based Bifunctional ADC Linker Benchmarked Using 89Zr－Desferal and Auristatin F－Conjugated Trastuzumab[J]．Cancer Res，2017，77(2):257-267.
[52]	Dijkers EC，Oude Munnink TH，Kosterink JG，et al.Biodistribution of 89Zr－trastuzumab and PET imaging of HER2－positive lesions in patients with metastatic breast cancer[J]．Clin Pharmacol Ther，2010，87(5):586-592.
[53]	O'Donoghue JA，Lewis JS，Pandit－Taskar N，et al.Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr－Trastuzumab in Patients with Esophagogastric Cancer[J]．J Nucl Med，2018，59(1):161-166.
[54]	Laforest R，Lapi SE，Oyama R，et al.^89ZrTrastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2－Positive Breast Cancer[J]．Mol Imaging Biol，2016，18(6):952-959.
[55]	Franklin MC，Carey KD，Vajdos FF，et al.Insights into ErbB signaling from the structure of the ErbB2－pertuzumab complex[J]．Cancer Cell，2004，5(4):317-328.
[56]	Yamashita－Kashima Y，Iijima S，Yorozu K，et al.Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2－positive human gastric cancer xenograft models[J]．Clin Cancer Res，2011，17(15):5060-5070.
[57]	Ulaner GA，Lyashchenko SK，Riedl C，et al.First－in－human HER2－targeted imaging using 89Zr－pertuzumab PET/CT: Dosimetry and clinical application in patients with breast cancer[J]．J Nucl Med，2018，59(6):900-906.
[58]	Zhou Y，Li G，Wu J，et al.Clinicopathological significance of E－cadherin, VEGF, and MMPs in gastric cancer[J]．Tumour Biol，2010，31(6):549-558.
[59]	Cross MJ，Claesson－Welsh L．FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition[J]．Trends Pharmacol Sci，2001，22(4):201-207.
[60]	Jüttner S，Wissmann C，Jons T，et al.Vascular endothelial growth factor－D and its receptor VEGFR－3: two novel independent prognostic markers in gastric adenocarcinoma[J]．J Clin Oncol，2006，24(2):228-240.
[61]	Zhu H，Zhao C，Liu F，et al.Radiolabeling and evaluation of (64)Cu－DOTA－F56 peptide targeting vascular endothelial growth factor receptor 1 in the molecular imaging of gastric cancer[J]．Am J Cancer Res，2015，5(11):3301-3310.
[62]	Friedman HS，Prados MD，Wen PY，et al.Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma[J]．J Clin Oncol，2009，27(28):4733-4740.
[63]	van der Bilt AR，Terwisscha van Scheltinga AG，Timmer－Bosscha H，et al.Measurement of tumor VEGF－A levels with 89Zr－bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model[J]．Clin Cancer Res，2012，18(22):6306-6314.
[64]	Jansen MH，Lagerweij T，Sewing AC，et al.Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr－Bevacizumab PET Imaging in Brain Tumor Models[J]．Mol Cancer Ther，2016，15(9):2166-7214.
[65]	van Es SC，Brouwers AH，Mahesh SVK，et al.89Zr－Bevacizumab PET: Potential Early Indicator of Everolimus Efficacy in Patients with Metastatic Renal Cell Carcinoma[J]．J Nucl Med，2017，58(6):905-910.
[66]	Sharma N，Adjei AA.In the clinic: ongoing clinical trials evaluating c－MET－inhibiting drugs[J]．Ther Adv Med Oncol，2011，3(1 Suppl):S37-S50.
[67]	Comoglio PM，Giordano S，Trusolino L．Drug development of MET inhibitors: targeting oncogene addiction and expedience[J]．Nat Rev Drug Discov，2008，7(6):504-516.
[68]	Ishibe S，Karihaloo A，Ma H，et al. Met and the epidermal growth factor receptor act cooperatively to regulate final nephron number and maintain collecting duct morphology[J]．Development，2009，136(2):337-345.
[69]	Riquelme I，Saavedra K，Espinoza JA，et al.Molecular classification of gastric cancer: Towards a pathway－driven targeted therapy[J]．Oncotarget，2015，6(28): 24750-24779.
[70]	Zhang Y，Jain RK，Zhu M．Recent Progress and Advances in HGF/MET－Targeted Therapeutic Agents for Cancer Treatment[J]．Biomedicines，2015，3(1):149-181.
[71]	Price EW，Carnazza KE，Carlin SD，et al.89Zr－DFO－AMG102 Immuno－PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection[J]．J Nucl Med，2017，58(9):1386-1394.
[72]	Annalisa Petrelli，Paola Circosta，Luisa Granziero，et al. Ab－induced ectodomain shedding mediates hepatocyte growth factor receptor down－regulation and hampers biological activity[J]. Proc Natl Acad Sci U S A. 2006 Mar 28; 103(13): 5090-5095. PMCID: PMC1458799
[73]	Merchant M，Ma X，Maun HR，et al.Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti－tumor activity as a therapeutic agent[J]．Proc Natl Acad Sci U S A，2013，110(32): E2987-E2996.
[74]	Perk LR，Stigter－van Walsum M，Visser GW，et al.Quantitative PET imaging of Met－expressing human cancer xenografts with 89Zr－labelled monoclonal antibody DN30[J]．Eur J Nucl Med Mol Imaging，2008，35(10):1857-1867.
[75]	Pool M，Terwisscha van Scheltinga AGT，Kol A，et al.89Zr－Onartuzumab PET imaging of c－MET receptor dynamics[J]．Eur J Nucl Med Mol Imaging，2017，44(8):1328-1336.
[76]	Zhang JR，Zhang XY，Chen XT，et al.Purification and partial characterization of a new group of gastric cancer associated antigens[J]．Chin Med J (Engl)，1991，104(3):212-216.
[77]	Guo DL，Dong M，Wang L，et al.Expression of gastric cancer－associated MG7 antigen in gastric cancer, precancerous lesions and H. pylori －associated gastric diseases[J]. World J Gastroenterol，2002，8(6):1009-1013.
[78]	Green MA，Mathias CJ，Neumann WL，et al.Potential gallium－68 tracers for imaging the heart with PET: evaluation of four gallium complexes with functionalized tripodal tris(salicylaldimine) ligands[J]．J Nucl Med，1993，34(2):228-233.
[79]	Li Z，Zuo XL，Li CQ，et al.In vivo molecular imaging of gastric cancer by targeting MG7 antigen with confocal laser endomicroscopy[J]．Endoscopy，2013，45(2):79-85.
[80]	Xu B, Li X, Yin J, et al.Evaluation of 68Ga－labeled MG7 antibody: a targeted probe for PET/CT imaging of gastric cancer[J]．Scientific Reports，2015，5:8626.

Please choose a citation manager

Content to export